CHICAGO - Gadopiclenol is emerging as an alternative gadolinium-based MRI contrast agent. To learn more about the product's potential, we spoke with Prof. Dr. Christiane Kuhl from the University Hospital Aachen in Germany at RSNA 2022.
Kuhl provides research update on gadolinium-based contrast agent
Dec 4, 2022
Latest in Market Analysis
SFR praises work of x-ray specialist Gabriel Kalifa
November 1, 2024
Clinical oncologist speaks about life in the U.K.
October 18, 2024
Nick Screaton becomes new BIR president
October 1, 2024
RCR President responds to Darzi diagnosis
September 23, 2024